Sutro Biopharma (STRO) Other Accumulated Expenses (2017 - 2026)

Sutro Biopharma has reported Other Accumulated Expenses for 9 years, with the latest figure at $2.9 million in Q4 2025.

• Quarterly Other Accumulated Expenses fell 27.34% year-over-year to $2.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.9 million (down 27.34% YoY) and the FY2025 annual result came in at $2.9 million, down 27.34% from the prior year.
• Other Accumulated Expenses declined to $2.9 million in Q4 2025 per STRO's latest filing, from $15.8 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $17.8 million in Q2 2025 and troughed at $185000.0 in Q1 2021.
• A 5-year average of $5.0 million and a median of $3.4 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2021 and 2022: Other Accumulated Expenses tumbled 91.39% in 2021, then jumped 1408.11% in 2022.
• Over 5 years, Other Accumulated Expenses stood at $2.8 million in 2021, then gained by 12.0% to $3.1 million in 2022, then gained by 26.53% to $3.9 million in 2023, then gained by 2.87% to $4.0 million in 2024, then fell by 27.34% to $2.9 million in 2025.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $2.9 million, $15.8 million, and $17.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.